Sheng Lim
4 Papers
Sheng Lim is an academic researcher. The author has contributed to research in topics: Medicine & Ocular hypertension. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial
Gus Gazzard,Gus Gazzard,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,David F. Garway-Heath,David F. Garway-Heath,Anurag Garg,Anurag Garg,Victoria Vickerstaff,Rachael Hunter,Gareth Ambler,Catey Bunce,Catey Bunce,Richard Wormald,Richard Wormald,Richard Wormald,Neil Nathwani,Keith Barton,Keith Barton,Gary S. Rubin,Marta Buszewicz,Rupert R A Bourne,David C Broadway,Amanda Davis,Hari Jayaram,Yuzhen Jiang,Sheng Lim,Joanna Liput,Timothy Manners,Stephen Morris,Nicholas G. Strouthidis,Sarah L Wilson,Haogang Zhu +32 more
TL;DR: Over 36 months, from an ophthalmology cost perspective, there was a 97% probability of selective laser trabeculoplasty as first treatment being more cost-effective than eye drops first at a willingness to pay of £20 000 per quality-adjusted life-year gained.
424
Primary Selective Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success, and Safety from the Laser in Glaucoma and Ocular Hypertension Trial.
Anurag Garg,Anurag Garg,Victoria Vickerstaff,Neil Nathwani,David F. Garway-Heath,David F. Garway-Heath,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,Gareth Ambler,Catey Bunce,Richard Wormald,Richard Wormald,Richard Wormald,Keith Barton,Keith Barton,Gus Gazzard,Gus Gazzard,Rupert R A Bourne,David C Broadway,Marta Buszewicz,Amanda Davis,Rachael Hunter,Hari Jayaram,Yuzhen Jiang,Sheng Lim,Joanna Liput,Timothy Manners,Stephen Morris,Gary S. Rubin,Nicholas G. Strouthidis,Sarah L Wilson,Haogang Zhu +31 more
TL;DR: Primary SLT achieved comparable early absolute IOP-lowering in OHT versus OAG eyes, and total SLT power and 2-month IOP were predictors of drop-free disease-control at 36 months after single SLT.
91
One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis
Alex J Tanner,Fadi Haddad,Julia A. Fajardo-Sánchez,Ethan Nguyen,K. X. Thong,Sarah Ah-Moye,N. Perl,M. Abu-Bakra,A Kulkarni,S. Trikha,Gerassimos Lascaratos,Miles Parnell,Obeda Kailani,Anthony J King,Pavi Agrawal,Richard Stead,K. Giannouladis,Ian A Rodrigues,Saurabh Goyal,Pirro G. Hysi,Sheng Lim,C. Yu-Wai-Man +21 more
TL;DR: The PreserFlo MicroShunt with MMC 0.4 mg/mL showed an overall success rate of 68.3% at 1 year, and led to significant IOP and medication reduction with a low rate of adverse effects.
Evaluating primary treatment for people presenting with advanced glaucoma: 5-year results of the Treatment of Advanced Glaucoma Study.
Anthony J King,Jemma Hudson,Augusto Azuara-Blanco,Jennifer Burr,Ashleigh Kernohant,Tara Homer,Hosein Shabaninejad,John M Sparrow,David Garway-Heath,Keith Barton,John Norrie,Tracey Davidson,Luke Vale,Graeme MacLennan,Anthony J King,Pavi Agrawal,Richard Stead,Nick Strouthidis,Shenton Chew,Chelvin C A Sng,Marta Toth,Gus Gazzard,A. Elkarmouty,Eleni Nikita,Giacinto Triolo,Soledad Aguilar-Munoa,Saurabh Goyal,Sheng Lim,Velota Sung,Imran Masood,N. Wride,Amanjeet Sandhu,Elizabeth Hill,John M Sparrow,Fiona Grey,Rupert R A Bourne,Gnanapragasam Nithyanandarajah,Catherine Willshire,Philip Bloom,Faisal Ahmed,Franesca Cordeiro,Laura Crawley,Eduardo Normando,Sally Ameen,Joanna Tryfinopoulou,Alistair Porteous,G. Jutley,Dimitrios Bessinis,James K Kirwan,Shahiba Begum,Anastasios Sepetis,Edward Rule,Richard Thornton,Andrew McNaught,Nitin Anand,Anil Negi,Obaid Kousha,M. Hovan,Roshini Sanders,Pankaj Kumar Agarwal,Andrew Tatham,Leon Au,C. Fenerty,Tanya Karaconji,Brett Drury,Duya Penmol,Ejaz Ansari,Albina Dardzhikova,Reza Moosavi,Richard Imonikhe,Prodromos Kontovourikis,Luke Membrey,Goncalo Almeida,James Tildsley,Augusto Azuara-Blanco,Angela Knox,Simon Rankin,S. Wilson,Avinash Prabhu,S. Mukherji,Amit Datta,Alisdair Fern,Joanna Liput,Tim Manners,Josh Pilling,Clare Stemp,Karen Martin,Tracey Nixon,Caroline Cobb,Alan R. Rotchford,S Sidiki,Atul Bansal,Royal Hallamshire,Graham Auger,Mary Freeman +94 more
TL;DR: At 5 years TAGS has demonstrated that primary trabeculectomy surgery is more effective in lowering IOP and preventing disease progression than primary medical treatment in patients presenting with advanced disease and has a similar safety profile.
7